Chiesi has made its biggest ever acquisition with the $1.48bn buyout of rare disease specialist company Amryt Pharma to further its US and rare disease ambitions.
The privately owned, Italy-headquartered company currently earns the lion’s share of its revenues from its portfolio of respiratory medicines in...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
